Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer

PLoS Computational Biology

Volumn 11, Issue 11, 2015, Pages

  Zhao, Chen ^a   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; COMPUTATION THEORY; COMPUTATIONAL METHODS; DISEASE CONTROL; DISEASES; ENDOTHELIAL CELLS; OXYGEN; RNA;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELLULAR ADAPTATION; COMPUTATIONAL MODELLING; ENDOTHELIAL-CELLS; HYPOXIA-INDUCIBLE FACTORS; MODELING PARAMETERS; PATHOPHYSIOLOGY; VASCULAR DISEASE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

STABILIZATION;

ARGONAUTE 1 PROTEIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LET 7 RNA; MICRORNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CELL FUNCTION; CELL NUCLEUS; COMPLEX FORMATION; COMPUTATIONAL MODEL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEEDBACK SYSTEM; GENETIC REGULATION; HYPOXIA; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONBIOLOGICAL MODEL; OXYGEN SENSING; PATHOPHYSIOLOGY; PROTEIN STABILITY; PROTEIN TRANSPORT; SIMULATION; VASCULAR DISEASE; BIOLOGICAL MODEL; BIOLOGY; CELL HYPOXIA; COMPUTER SIMULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL HYPOXIA; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASMS; PERIPHERAL ARTERIAL DISEASE; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949254964     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004612     Document Type: Article

References (111)

1. Ke Q, Costa M, Hypoxia-inducible factor-1 (HIF-1). Molecular pharmacology. 2006;70(5):1469–80. doi: 10.1124/mol.106.027029 16887934.
2. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ, An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic acids research. 2009;37(14):4587–602. doi: 10.1093/nar/gkp425 19491311; PubMed Central PMCID: PMC2724271.
3. Semenza GL, Hypoxia-inducible factor 1 and cardiovascular disease. Annual review of physiology. 2014;76:39–56. doi: 10.1146/annurev-physiol-021113-170322 23988176.
4. Wang GL, Jiang BH, Rue EA, Semenza GL, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(12):5510–4. 7539918; PubMed Central PMCID: PMC41725.
5. Semenza GL, Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399–408. doi: 10.1016/j.cell.2012.01.021 22304911; PubMed Central PMCID: PMC3437543.
6. Wenger RH, Stiehl DP, Camenisch G, Integration of oxygen signaling at the consensus HRE. Science's STKE: signal transduction knowledge environment. 2005;2005(306):re12. doi: 10.1126/stke.3062005re12 16234508.
7. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA, Vascular endothelial growth factor and angiogenesis. Pharmacological reviews. 2004;56(4):549–80. doi: 10.1124/pr.56.4.3 15602010.
8. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. The EMBO journal. 2004;23(20):4051–60. doi: 10.1038/sj.emboj.7600385 15372072; PubMed Central PMCID: PMC524334.
9. Borchert GM, Lanier W, Davidson BL, RNA polymerase III transcribes human microRNAs. Nature structural & molecular biology. 2006;13(12):1097–101. doi: 10.1038/nsmb1167 17099701.
10. Macfarlane LA, Murphy PR, MicroRNA: Biogenesis, Function and Role in Cancer. Current genomics. 2010;11(7):537–61. doi: 10.2174/138920210793175895 21532838; PubMed Central PMCID: PMC3048316.
11. Bartel DP, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. 14744438.
12. Murchison EP, Hannon GJ, miRNAs on the move: miRNA biogenesis and the RNAi machinery. Current opinion in cell biology. 2004;16(3):223–9. doi: 10.1016/j.ceb.2004.04.003 15145345.
13. Sasaki T, Shiohama A, Minoshima S, Shimizu N, Identification of eight members of the Argonaute family in the human genome. Genomics. 2003;82(3):323–30. 12906857.
14. Wang B, Li S, Qi HH, Chowdhury D, Shi Y, Novina CD, Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins. Nature structural & molecular biology. 2009;16(12):1259–66. doi: 10.1038/nsmb.1712 19946268.
15. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R, Control of translation and mRNA degradation by miRNAs and siRNAs. Genes & development. 2006;20(5):515–24. doi: 10.1101/gad.1399806 16510870.
16. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305(5689):1437–41. doi: 10.1126/science.1102513 15284456.
17. Zhou X, Yuan P, He Y, Role of microRNAs in peripheral artery disease (review). Molecular medicine reports. 2012;6(4):695–700. doi: 10.3892/mmr.2012.978 22767222.
18. Liao YC, Wang YS, Guo YC, Lin WL, Chang MH, Juo SH, Let-7g improves multiple endothelial functions through targeting transforming growth factor-beta and SIRT-1 signaling. Journal of the American College of Cardiology. 2014;63(16):1685–94. doi: 10.1016/j.jacc.2013.09.069 24291274.
19. Otsuka M, Zheng M, Hayashi M, Lee JD, Yoshino O, Lin S, et al. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. The Journal of clinical investigation. 2008;118(5):1944–54. doi: 10.1172/JCI33680 18398510; PubMed Central PMCID: PMC2289794.
20. Suarez Y, Sessa WC, MicroRNAs as novel regulators of angiogenesis. Circulation research. 2009;104(4):442–54. doi: 10.1161/CIRCRESAHA.108.191270 19246688; PubMed Central PMCID: PMC2760389.
21. Chen Z, Lai TC, Jan YH, Lin FM, Wang WC, Xiao H, et al. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. The Journal of clinical investigation. 2013;123(3):1057–67. doi: 10.1172/JCI65344 23426184; PubMed Central PMCID: PMC3582133.
22. Arkin AP, Schaffer DV, Network news: innovations in 21st century systems biology. Cell. 2011;144(6):844–9. doi: 10.1016/j.cell.2011.03.008 21414475.
23. Cheng FH, Aguda BD, Tsai JC, Kochanczyk M, Lin JM, Chen GC, et al. A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells. PloS one. 2014;9(12):e116050. doi: 10.1371/journal.pone.0116050 25545504; PubMed Central PMCID: PMC4278842.
24. Jolly MK, Huang B, Lu M, Mani SA, Levine H, Ben-Jacob E, Towards elucidating the connection between epithelial-mesenchymal transitions and stemness. Journal of the Royal Society, Interface / the Royal Society. 2014;11(101):20140962. doi: 10.1098/rsif.2014.0962 25339690; PubMed Central PMCID: PMC4223923.
25. Kim Y, Powathil G, Kang H, Trucu D, Kim H, Lawler S, et al. Strategies of eradicating glioma cells: a multi-scale mathematical model with MiR-451-AMPK-mTOR control. PloS one. 2015;10(1):e0114370. doi: 10.1371/journal.pone.0114370 25629604; PubMed Central PMCID: PMC4309536.
26. Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, Barrett JC, Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Molecular biology of the cell. 2004;15(7):3042–52. doi: 10.1091/mbc.E03-12-0897 15107465; PubMed Central PMCID: PMC452562.
27. Qutub AA, Popel AS, A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. Journal of cell science. 2006;119(Pt 16):3467–80. doi: 10.1242/jcs.03087 16899821; PubMed Central PMCID: PMC2129128.
28. Nguyen LK, Cavadas MA, Scholz CC, Fitzpatrick SF, Bruning U, Cummins EP, et al. A dynamic model of the hypoxia-inducible factor 1alpha (HIF-1alpha) network. Journal of cell science. 2013;126(Pt 6):1454–63. doi: 10.1242/jcs.119974 23390316.
29. Qutub AA, Popel AS, Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. Biochimica et biophysica acta. 2007;1773(10):1511–25. doi: 10.1016/j.bbamcr.2007.07.004 17720260; PubMed Central PMCID: PMC2094118.
30. Qutub AA, Popel AS, Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Molecular and cellular biology. 2008;28(16):5106–19. doi: 10.1128/MCB.00060-08 18559422; PubMed Central PMCID: PMC2519710.
31. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, et al. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. The Biochemical journal. 2004;381(Pt 3):761–7. doi: 10.1042/BJ20040620 15104534; PubMed Central PMCID: PMC1133886.
32. Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC, et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Molecular and cellular biology. 2011;31(19):4087–96. doi: 10.1128/MCB.01276-10 21807897; PubMed Central PMCID: PMC3187364.
33. Chamboredon S, Ciais D, Desroches-Castan A, Savi P, Bono F, Feige JJ, et al. Hypoxia-inducible factor-1alpha mRNA: a new target for destabilization by tristetraprolin in endothelial cells. Molecular biology of the cell. 2011;22(18):3366–78. doi: 10.1091/mbc.E10-07-0617 21775632; PubMed Central PMCID: PMC3172262.
34. Kim TW, Yim S, Choi BJ, Jang Y, Lee JJ, Sohn BH, et al. Tristetraprolin regulates the stability of HIF-1alpha mRNA during prolonged hypoxia. Biochemical and biophysical research communications. 2010;391(1):963–8. doi: 10.1016/j.bbrc.2009.11.174 19962963.
35. Ciais D, Cherradi N, Bailly S, Grenier E, Berra E, Pouyssegur J, et al. Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. Oncogene. 2004;23(53):8673–80. doi: 10.1038/sj.onc.1207939 15467755.
36. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and cellular biology. 1996;16(9):4604–13. 8756616; PubMed Central PMCID: PMC231459.
37. Ameln H, Gustafsson T, Sundberg CJ, Okamoto K, Jansson E, Poellinger L, et al. Physiological activation of hypoxia inducible factor-1 in human skeletal muscle. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2005;19(8):1009–11. doi: 10.1096/fj.04-2304fje 15811877.
38. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer cell. 2004;6(5):485–95. doi: 10.1016/j.ccr.2004.09.026 15542432.
39. Skuli N, Majmundar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, et al. Endothelial HIF-2alpha regulates murine pathological angiogenesis and revascularization processes. The Journal of clinical investigation. 2012;122(4):1427–43. doi: 10.1172/JCI57322 22426208; PubMed Central PMCID: PMC3314446.
40. Zisoulis DG, Kai ZS, Chang RK, Pasquinelli AE, Autoregulation of microRNA biogenesis by let-7 and Argonaute. Nature. 2012;486(7404):541–4. doi: 10.1038/nature11134 22722835; PubMed Central PMCID: PMC3387326.
41. Tokumaru S, Suzuki M, Yamada H, Nagino M, Takahashi T, let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis. 2008;29(11):2073–7. doi: 10.1093/carcin/bgn187 18700235.
42. Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E, P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Molecular and cellular biology. 2007;27(11):3970–81. doi: 10.1128/MCB.00128-07 17403906; PubMed Central PMCID: PMC1900022.
43. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R, MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nature cell biology. 2005;7(7):719–23. doi: 10.1038/ncb1274 15937477; PubMed Central PMCID: PMC1855297.
44. Brengues M, Teixeira D, Parker R, Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies. Science. 2005;310(5747):486–9. doi: 10.1126/science.1115791 16141371; PubMed Central PMCID: PMC1863069.
45. Yin KJ, Olsen K, Hamblin M, Zhang J, Schwendeman SP, Chen YE, Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. The Journal of biological chemistry. 2012;287(32):27055–64. doi: 10.1074/jbc.M112.364414 22692216; PubMed Central PMCID: PMC3411046.
46. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PloS one. 2006;1:e116. doi: 10.1371/journal.pone.0000116 17205120; PubMed Central PMCID: PMC1762435.
47. Jiang BH, Semenza GL, Bauer C, Marti HH, Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. The American journal of physiology. 1996;271(4 Pt 1):C1172–80. 8897823.
48. Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J, Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. American journal of physiology Endocrinology and metabolism. 2009;296(2):E333–42. doi: 10.1152/ajpendo.90760.2008 19066318; PubMed Central PMCID: PMC2645021.
49. He Q, Gao Z, Yin J, Zhang J, Yun Z, Ye J, Regulation of HIF-1α activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. American journal of physiology Endocrinology and metabolism. 2011;300(5):E877–85. doi: 10.1152/ajpendo.00626.2010 21343542; PubMed Central PMCID: PMC3093977.
50. Zhou S, Gu L, He J, Zhang H, Zhou M, MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Molecular and cellular biology. 2011;31(24):4928–37. doi: 10.1128/MCB.06085-11 21986500; PubMed Central PMCID: PMC3233029.
51. Liu Q, Xu Z, Mao S, Chen W, Zeng R, Zhou S, et al. Effect of hypoxia on hypoxia inducible factor-1alpha, insulin-like growth factor I and vascular endothelial growth factor expression in hepatocellular carcinoma HepG2 cells. Oncology letters. 2015;9(3):1142–8. doi: 10.3892/ol.2015.2879 25663870; PubMed Central PMCID: PMC4315007.
52. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130(4):691–703. doi: 10.1016/j.cell.2007.06.054 17719546; PubMed Central PMCID: PMC3010851.
53. Yuan Y, Hilliard G, Ferguson T, Millhorn DE, Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. The Journal of biological chemistry. 2003;278(18):15911–6. doi: 10.1074/jbc.M300463200 12606543.
54. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK, FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes & development. 2002;16(12):1466–71. doi: 10.1101/gad.991402 12080085; PubMed Central PMCID: PMC186346.
55. Kut C, Mac Gabhann F, Popel AS, Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. British journal of cancer. 2007;97(7):978–85. doi: 10.1038/sj.bjc.6603923 17912242; PubMed Central PMCID: PMC2360423.
56. Sharkey A, Day K, McPherson A, Malik S, Licence D, Smith S, et al. Vascular Endothelial Growth Factor Expression in Human Endometrium Is Regulated by Hypoxia 1. The Journal of Clinical Endocrinology & Metabolism. 2000;85(1):402–9.
57. Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ, Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. International journal of oncology. 2008;32(3):585–92. 18292935
58. Ahluwalia A, Jones MK, Tarnawski AS, Key role of endothelial importin-alpha in VEGF expression and gastric angiogenesis: novel insight into aging gastropathy. American journal of physiology Gastrointestinal and liver physiology. 2014;306(4):G338–45. doi: 10.1152/ajpgi.00382.2013 24356884.
59. Zhang Z, Qin YW, Brewer G, Jing Q, MicroRNA degradation and turnover: regulating the regulators. Wiley interdisciplinary reviews RNA. 2012;3(4):593–600. doi: 10.1002/wrna.1114 22461385; PubMed Central PMCID: PMC3635675.
60. Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 2013;34(2):426–35. doi: 10.1093/carcin/bgs333 23104180.
61. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S, MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60(4):1314–23. doi: 10.2337/db10-1557 21357793; PubMed Central PMCID: PMC3064105.
62. Ho JJ, Metcalf JL, Yan MS, Turgeon PJ, Wang JJ, Chalsev M, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. The Journal of biological chemistry. 2012;287(34):29003–20. doi: 10.1074/jbc.M112.373365 22745131; PubMed Central PMCID: PMC3436557.
63. van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature communications. 2014;5:5203. doi: 10.1038/ncomms6203 25351418; PubMed Central PMCID: PMC4255228.
64. Bandara V, Michael MZ, Gleadle JM, Hypoxia represses microRNA biogenesis proteins in breast cancer cells. BMC cancer. 2014;14:533. doi: 10.1186/1471-2407-14-533 25052766; PubMed Central PMCID: PMC4223767.
65. Hazarika S, Farber CR, Dokun AO, Pitsillides AN, Wang T, Lye RJ, et al. MicroRNA-93 controls perfusion recovery after hindlimb ischemia by modulating expression of multiple genes in the cell cycle pathway. Circulation. 2013;127(17):1818–28. doi: 10.1161/CIRCULATIONAHA.112.000860 23559675; PubMed Central PMCID: PMC3856290.
66. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. The EMBO journal. 2007;26(15):3699–708. doi: 10.1038/sj.emboj.7601790 17627278; PubMed Central PMCID: PMC1949005.
67. Ye ZL, Huang Y, Li LF, Zhu HL, Gao HX, Liu H, et al. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma. Acta pharmacologica Sinica. 2015. doi: 10.1038/aps.2015.18 25937637.
68. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, et al. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochemical and biophysical research communications. 2008;368(2):243–8. doi: 10.1016/j.bbrc.2008.01.074 18222171.
69. Wu S, Yu W, Qu X, Wang R, Xu J, Zhang Q, et al. Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation. Journal of hematology & oncology. 2014;7:40. doi: 10.1186/1756-8722-7-40 24886719; PubMed Central PMCID: PMC4108130.
70. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(17):7904–9. doi: 10.1073/pnas.0908441107 20385818; PubMed Central PMCID: PMC2867889.
71. Kurosh Ameri ALH, Schwab M, Anoxia. In: Encyclopedia of Cancer. 1. third ed: Springer Science & Business Media; 2011. p. 193–8.
72. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710–3. doi: 10.1126/science.1174381 19460962.
73. Small EM, Frost RJ, Olson EN, MicroRNAs add a new dimension to cardiovascular disease. Circulation. 2010;121(8):1022–32. doi: 10.1161/CIRCULATIONAHA.109.889048 20194875; PubMed Central PMCID: PMC2847432.
74. Stather PW, Sylvius N, Wild JB, Choke E, Sayers RD, Bown MJ, Differential microRNA expression profiles in peripheral arterial disease. Circulation Cardiovascular genetics. 2013;6(5):490–7. doi: 10.1161/CIRCGENETICS.111.000053 24129592.
75. Ross CR, Brennan-Laun SE, Wilson GM, Tristetraprolin: roles in cancer and senescence. Ageing research reviews. 2012;11(4):473–84. doi: 10.1016/j.arr.2012.02.005 22387927; PubMed Central PMCID: PMC3376680.
76. Sanduja S, Blanco FF, Young LE, Kaza V, Dixon DA, The role of tristetraprolin in cancer and inflammation. Frontiers in bioscience. 2012;17:174–88. 22201737; PubMed Central PMCID: PMC3461960.
77. Rabinowitz MH, Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. Journal of medicinal chemistry. 2013;56(23):9369–402. doi: 10.1021/jm400386j 23977883.
78. Brooks SA, Connolly JE, Rigby WF, The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. Journal of immunology. 2004;172(12):7263–71. 15187101.
79. Taylor GA, Thompson MJ, Lai WS, Blackshear PJ, Phosphorylation of tristetraprolin, a potential zinc finger transcription factor, by mitogen stimulation in intact cells and by mitogen-activated protein kinase in vitro. The Journal of biological chemistry. 1995;270(22):13341–7. 7768935.
80. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Molecular and cellular biology. 2006;26(6):2399–407. doi: 10.1128/MCB.26.6.2399-2407.2006 16508014; PubMed Central PMCID: PMC1430282.
81. Gebeshuber CA, Zatloukal K, Martinez J, miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO reports. 2009;10(4):400–5. doi: 10.1038/embor.2009.9 19247375; PubMed Central PMCID: PMC2672883.
82. Stather PW, Sylvius N, Sidloff DA, Dattani N, Verissimo A, Wild JB, et al. Identification of microRNAs associated with abdominal aortic aneurysms and peripheral arterial disease. The British journal of surgery. 2015;102(7):755–66. doi: 10.1002/bjs.9802 25832031.
83. Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, et al. Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vascular medicine. 2012;17(2):94–100. doi: 10.1177/1358863X11436334 22402934; PubMed Central PMCID: PMC3609421.
84. Barh D, Malhotra R, Ravi B, Sindhurani P, MicroRNA let-7: an emerging next-generation cancer therapeutic. Current oncology. 2010;17(1):70–80. 20179807; PubMed Central PMCID: PMC2826782.
85. Aronow WS, Peripheral arterial disease in the elderly. Clinical interventions in aging. 2007;2(4):645–54. 18225466; PubMed Central PMCID: PMC2686340.
86. Lawler PR, Lawler J, Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harbor perspectives in medicine. 2012;2(5):a006627. doi: 10.1101/cshperspect.a006627 22553494; PubMed Central PMCID: PMC3331684.
87. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB, Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circulation research. 2006;99(2):140–8. doi: 10.1161/01.RES.0000232352.90786.fa 16778129.
88. Collinson DJ, Donnelly R, Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. 2004;28(1):9–23. doi: 10.1016/j.ejvs.2004.03.021 15177227.
89. Mac Gabhann F, Qutub AA, Annex BH, Popel AS, Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley interdisciplinary reviews Systems biology and medicine. 2010;2(6):694–707. doi: 10.1002/wsbm.92 20890966; PubMed Central PMCID: PMC2990677.
90. Schainfeld RM, Management of peripheral arterial disease and intermittent claudication. The Journal of the American Board of Family Practice / American Board of Family Practice. 2001;14(6):443–50. 11757887.
91. Minar E, Critical limb ischaemia. Hamostaseologie. 2009;29(1):102–9. 19151858.
92. Annex BH, Therapeutic angiogenesis for critical limb ischaemia. Nature reviews Cardiology. 2013;10(7):387–96. doi: 10.1038/nrcardio.2013.70 23670612.
93. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. The Journal of clinical investigation. 2010;120(11):4141–54. doi: 10.1172/JCI42980 20972335; PubMed Central PMCID: PMC2964978.
94. Wang H, Flach H, Onizawa M, Wei L, McManus MT, Weiss A, Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nature immunology. 2014;15(4):393–401. doi: 10.1038/ni.2846 24608041; PubMed Central PMCID: PMC3996831.
95. Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(37):14082–7. doi: 10.1073/pnas.0804597105 18779589; PubMed Central PMCID: PMC2544582.
96. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010;115(23):4944–50. doi: 10.1182/blood-2010-01-264812 20299512.
97. Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. The EMBO journal. 2009;28(18):2719–32. doi: 10.1038/emboj.2009.214 19696742; PubMed Central PMCID: PMC2750010.
98. Wu C, So J, Davis-Dusenbery BN, Qi HH, Bloch DB, Shi Y, et al. Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2. Molecular and cellular biology. 2011;31(23):4760–74. doi: 10.1128/MCB.05776-11 21969601; PubMed Central PMCID: PMC3232924.
99. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013;497(7449):383–7. doi: 10.1038/nature12080 23636329; PubMed Central PMCID: PMC3717558.
100. Wang C, Yi M, Yang K, Yang L, Time delay induced transition of gene switch and stochastic resonance in a genetic transcriptional regulatory model. BMC systems biology. 2012;6 Suppl 1:S9. doi: 10.1186/1752-0509-6-S1-S9 23046840; PubMed Central PMCID: PMC3403677.
101. Baker RE, Schnell S, Maini PK, Mathematical models for somite formation. Current topics in developmental biology. 2008;81:183–203. doi: 10.1016/S0070-2153(07)81006-4 18023728; PubMed Central PMCID: PMC2754719.
102. Hester SD, Belmonte JM, Gens JS, Clendenon SG, Glazier JA, A multi-cell, multi-scale model of vertebrate segmentation and somite formation. PLoS computational biology. 2011;7(10):e1002155. doi: 10.1371/journal.pcbi.1002155 21998560; PubMed Central PMCID: PMC3188485.
103. Ota K, Yamada T, Yamanishi Y, Goto S, Kanehisa M, Comprehensive analysis of delay in transcriptional regulation using expression profiles. Genome Informatics. 2003;14:302–3.
104. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(10):3627–32. doi: 10.1073/pnas.0500613102 15738415; PubMed Central PMCID: PMC552785.
105. Bissels U, Wild S, Tomiuk S, Holste A, Hafner M, Tuschl T, et al. Absolute quantification of microRNAs by using a universal reference. Rna. 2009;15(12):2375–84. doi: 10.1261/rna.1754109 19861428; PubMed Central PMCID: PMC2779673.
106. Osella M, Bosia C, Cora D, Caselle M, The role of incoherent microRNA-mediated feedforward loops in noise buffering. PLoS computational biology. 2011;7(3):e1001101. doi: 10.1371/journal.pcbi.1001101 21423718; PubMed Central PMCID: PMC3053320.
107. Giampieri E, Remondini D, de Oliveira L, Castellani G, Lio P, Stochastic analysis of a miRNA-protein toggle switch. Molecular bioSystems. 2011;7(10):2796–803. doi: 10.1039/c1mb05086a 21717010.
108. Mac Gabhann F, Yang MT, Popel AS, Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochimica et biophysica acta. 2005;1746(2):95–107. doi: 10.1016/j.bbamcr.2005.09.004 16257459.
109. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Corrigendum: Global quantification of mammalian gene expression control. Nature. 2013;495(7439):126–7. doi: 10.1038/nature11848 23407496.
110. Yang E, van Nimwegen E, Zavolan M, Rajewsky N, Schroeder M, Magnasco M, et al. Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. Genome research. 2003;13(8):1863–72. doi: 10.1101/gr.1272403 12902380; PubMed Central PMCID: PMC403777.
111. Gantier MP, McCoy CE, Rusinova I, Saulep D, Wang D, Xu D, et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic acids research. 2011;39(13):5692–703. doi: 10.1093/nar/gkr148 21447562; PubMed Central PMCID: PMC3141258.